New hope for women at high risk of breast cancer?
NCT ID NCT04821141
Summary
This study is testing whether a combination of two hormone medications (bazedoxifene and conjugated estrogens) can reduce markers of breast cancer risk in women who are at increased risk and experiencing menopausal hot flashes. About 120 women will be randomly assigned to take the medication or be in a waitlist group for 6 months. Researchers will measure changes in breast tissue density and cell growth markers to see if the treatment lowers risk.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Northwestern Medical Center
Chicago, Illinois, 60601, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
University of California San Francisco
San Francisco, California, 94115, United States
-
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
Conditions
Explore the condition pages connected to this study.